跳至主要内容
临床试验/KCT0012265
KCT0012265进行中(未招募)不适用

Fourteen-day amoxicillin- or tetracycline-containing bismuth quadruple therapy versus 14-day metronidazole based triple therapy as a first-line treatment for clarithromycin resistant Helicobacter pylori infection : A multicenter randomized controlled trial

Dong-A University Hospital0 个研究点目标入组 198 人开始时间: 2022年12月23日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
198

研究概览

简要总结

A total of 198 patients with clarithromycin-resistant Helicobacter pylori infection were randomly assigned in a 1:1:1 ratio to the PAM (n=66), PAM-B (n=66), and PBMT (n=66) groups. The overall eradication rate was 88.8%. In the intention-to-treat (ITT) analysis, eradication rates were 68.2% in the PAM group, 84.7% in the PAM-B group, and 81.8% in the PBMT group. The PAM-B group showed a significantly higher eradication rate than the PAM group (p=0.024), with no significant difference between the PAM-B and PBMT groups (p=0.640). In the per-protocol (PP) analysis, eradication rates were 75.4% (PAM), 96.5% (PAM-B, p=0.001 vs. PAM), and 94.6% (PBMT, p=0.004 vs. PAM), with no significant difference between PAM-B and PBMT (p=0.633). Regarding adverse events, nausea and vomiting were significantly less frequent in the PAM-B group (6.8%) than in the PBMT group (25.0%, p=0.007). Severe adverse events were rare, and all symptoms resolved after discontinuation of therapy.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
18(Year) 至 80(Year)(—)
性别
All

入选标准

  • ? Adults aged 18 to 80 years of both sexes. ? Patients diagnosed with Helicobacter pylori infection via endoscopy, confirmed by at least one of the following methods: histology, rapid urease test, serology, or urea breath test. ? Patients with clarithromycin resistance confirmed by dual-priming oligonucleotide polymerase chain reaction (DPO-PCR). ? Patients who provided written informed consent after receiving a full explanation of the study objectives and procedures.

排除标准

  • ? Patients with a history of prior Helicobacter pylori eradication therapy. ? Patients with a history of gastric surgery (e.g., gastrectomy). ? Patients with severe hepatic or renal impairment. ? Patients with a history of antibiotic allergy. ? Patients who had taken antibiotics within 4 weeks prior to study enrollment. ? Pregnant or lactating women.

研究组 & 干预措施

Drug : This study was a prospective, randomized controlled trial comparing three oral eradication regimens in patients with clarithromycin-resistant Helicobacter pylori (H. pylori) infection. All medications were administered orally, and the treatment duration was 14 days for all three arms.

干预措施: Drug : This study was a prospective, randomized controlled trial comparing three oral eradication regimens in patients with clarithromycin-resistant Helicobacter pylori (H. pylori) infection. All medications were administered orally, and the treatment duration was 14 days for all three arms.

研究者

相似试验